Pharmaceuticals

Ayr Wellness Inc.

Ayr Wellness Inc. released FY2025 Q1 earnings on September 12 (EST), actual revenue USD 107.31 M (forecast USD 109.4 M), actual EPS USD -0.4892

Ayr Wellness Inc. released FY2024 Q4 earnings during market hours on March 6 (EST), actual revenue 113.96 M USD (forecast 114.3 M USD), actual EPS -1.4027 USD

Ayr Wellness Inc. released FY2024 annual earnings on March 6 During-Market (EST), actual revenue 463.63 M USD (forecast 463.98 M USD), actual EPS -3.2419 USD

Ayr Wellness Inc. to Release FY2024 Q4 Earnings on March 6 During-Market EST, Forecast Revenue 114.08 M USD

Ayr Wellness Inc. released FY2024 Q3 earnings on November 13 Pre-Market (EST), actual revenue 114.33 MUSD (forecast 121.02 MUSD), actual EPS -0.4408 USD

Ayr Wellness Inc. released its Q3 2024 earnings on November 13, 2024 (EST), with actual revenue of 349.68M USD and EPS of -1.864

Ayr Wellness Inc. to Release FY2024 Q3 Earnings on November 13, Pre-Market EST; Forecast Revenue 121.02 M USD

AYR Wellness Inc. Obtains Conditional Approval for Medical Cannabis Business in Virginia

AYR Wellness Inc. Expands Cannabis Dispensaries in Florida

AYR Wellness announces Q2 2024 financial results

Resignation of Jonathan Sandelman, Director and CEO of Ayr Wellness Inc.

Increase in short positions for Ayr Wellness Inc.

OPTIMI HEALTH CORP

Silexion Therapeutics

FLAG SHIP ACQUISITION CORPORATION COM USD0.001 (SUB/RIGHT 31/03/2026)

Micware

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

HCW Biologics

GCL Global

Jupiter Neurosciences

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

CS精准医

HCWC

AYRWF

A new study by The Wellness Company, led by Dr. Peter McCullough, shows that the off-label use of Ivermectin and Mebendazole has an 84% clinical benefit ratio in cancer treatment. Analyzing 197 patients, 48% reported cancer regression or no evidence of disease, while 36% experienced stability. The study highlights the need for further scientific investigation into these medications as potential cancer treatments, amidst growing distrust in the healthcare system. The Wellness Company offers a 90-day supply of these medications, emphasizing their safety and efficacy.

ZeroHedge

Healthy Choice Wellness

Wellness & Beauty Solutions Ltd.

iShares Global Healthcare

iShares US Healthcare Providers

SPDR S&P Health

Health Care Select Sector SPDR

GROUNDBREAKING NEW STUDY REGARDING IVERMECTIN AND CANCER

AYR Wellness Announces Closing of Exit Facility and Related Transactions | AYRWF Stock News

StockTitan

AYR Wellness Announces Closing of Exit Facility and Related Transactions | AYRWF Stock News

NEPTF

Numinus Refocuses on Psychedelic Clinical Research Amid Audit and TSX Delisting Review

Tip Ranks

Neptune Wellness Solutions Inc.

Numinus Refocuses on Psychedelic Clinical Research Amid Audit and TSX Delisting Review

Pangea Wellness Plans Rebrand as The Precision Peptide Company

Pangea Wellness Plans Rebrand as The Precision Peptide Company

Massachusetts regulators are considering a freeze on new cannabis grow licenses to stabilize the struggling market, which faces high operational costs, regulatory challenges, and an oversupply of product. The industry has seen several closures, including Ayr Wellness' facility in Milford, due to declining wholesale prices.

Mass. cannabis regulators consider freezing grow licenses

In Missouri on February 5, 2026, Standard Wellness Holdings, LLC revealed a strategic collaboration with the renowned concentrate brand DABSTRACT, a subsidiary of UGC Inc. This partnership aims to introduce the terpene-rich products of DABSTRACT to a wider market. Standard Wellness stands as a prominent player in the cannabis industry, emphasizing vertical integration. The move signifies a significant alliance in the sector, underlining the growing importance of terpene-focused offerings.

Unusual Whales

Standard Wellness partners with DABSTRACT to expand concentrate offerings in Missouri. Date: Feb. 5, 2026. Leading cannabis company.

Empowered Mind & Wellness is introducing EXOMIND, an FDA-cleared, non-invasive brain stimulation procedure aimed at alleviating mental health issues such as depression and anxiety. Co-founders Dr. Monica Faria and Dr. Michael Dekker emphasize a personalized approach to treatment. The clinic will host an Open House on February 12, showcasing EXOMIND with demonstrations, refreshments, and special pricing. This innovative treatment offers a medication-free option for improving mental health, with reported benefits including better sleep and increased energy.

prnewswire

11:45 ET
			
			
				Empowered Mind & Wellness Brings Next-Generation Technology to Optimize Mental Health

Ayr Wellness Inc.(AYRWF.US)

GROUNDBREAKING NEW STUDY REGARDING IVERMECTIN AND CANCER

AYR Wellness Announces Closing of Exit Facility and Related Transactions | AYRWF Stock News

Numinus Refocuses on Psychedelic Clinical Research Amid Audit and TSX Delisting Review

Pangea Wellness Plans Rebrand as The Precision Peptide Company

Mass. cannabis regulators consider freezing grow licenses

Standard Wellness partners with DABSTRACT to expand concentrate offerings in Missouri. Date: Feb. 5, 2026. Leading cannabis company.

11:45 ET Empowered Mind & Wellness Brings Next-Generation Technology to Optimize Mental Health